Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/6538


Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use


Description: With CML’s relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient in size to allow companies to rapidly recoup their investment. Accordingly, only a handful of drugs have been approved for chronic leukemia in the last decade. However, since the launch of Novartis’ Gleevec (imatinib mesylate), significant revenues have been accrued, drawing industry attention to the CML market. - Provides a full breakdown of the Gleevec sales phenomenon, with detailed explanations and analysis. - Looks at the CML pipeline and provides product profiles, clinical data and forecast revenues to 2010. - Assesses the CML market’s future based on the attention that Gleevec has provided and where the attention will likely move in the future. Genta/Aventis’ Genasense (augmerosen) is forecast significant revenues in CML due to its chemosensitizing activity with most cytotoxic agents. Gleevec resistance in blast phase CML will provide new products with opportunity to gain market share and establish a strong position. The CML market represents a strong market for future development, however most of the lucrative revenue streams can be found through off-label drug usage in the acute leukemias.Access insights into the developmental gains available through CML and into the path to a successful revenue stream. Identify how targeting CML can provide significant sales gains through off-label usage in AML. Define the gaps in the CML market opening via Gleevec-resistant patient populations, and identify new opportunities for drug development.


Contents: Overview Introduction

With CML’s relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient in size to allow companies to rapidly recoup their investment. Accordingly, only a handful of drugs have been approved for chronic leukemia in the last decade. However, since the launch of Novartis’ Gleevec (imatinib mesylate), significant revenues have been accrued, drawing industry attention to the CML market.

Scope

  • Provides a full breakdown of the Gleevec sales phenomenon, with detailed explanations and analysis.

  • Looks at the CML pipeline and provides product profiles, clinical data and forecast revenues to 2010.

  • Assesses the CML market’s future based on the attention that Gleevec has provided and where the attention will likely move in the future.

Report Highlights

Genta/Aventis’ Genasense (augmerosen) is forecast significant revenues in CML due to its chemosensitizing activity with most cytotoxic agents.

Reasons to Purchase

  • Access insights into the developmental gains available through CML and into the path to a successful revenue stream.

  • Identify how targeting CML can provide significant sales gains through off-label usage in AML.

  • Define the gaps in the CML market opening via Gleevec-resistant patient populations, and identify new opportunities for drug development.

Report Highlights

Gleevec resistance in blast phase CML will provide new products with opportunity to gain market share and establish a strong position.

The CML market represents a strong market for future development, however most of the lucrative revenue streams can be found through off-label drug usage in the acute leukemias.

INTRODUCTION TO CHRONIC MYELOID LEUKEMIA

A description of chronic myeloid leukemia (CML), its market and historic therapies

GLEEVEC CASE STUDY

Analysis of the developmental and market strategies that have contributed to the success of Gleevec

CML PIPELINE

Overview of the key compounds in development for CML, with forecasts to 2010

  • Decitabine
  • Genasense
  • PEG-Intron
THE FUTURE CML MARKET

An assessment of the dynamics of the CML market

DATASETS Table 1: Current gold-standard therapies for CML, 2002 Table 2: Quarterly sales data for Gleevec since launch Table 3: Global forecasts for Gleevec, 2002-2010 Table 4: Late-stage developmental compounds for CML, 2002 Table 5: The number of compounds in development for the differing leukemia indications, 2002 Table 6: Global forecasts for decitabine, 2004-2010 Table 7: Global forecasts for Genasense, 2004-2010 Figure 1: The typical progression of CML Figure 2: Gleevec’s proposed mechanism of action Figure 3: Comparison of the niche and major markets, and the benefits that each hold Figure 4: The underlying strategies that Novartis has undertaken to market Gleevec Figure 5: Key factors in the relative success of decitabine Figure 6: Key factors in the relative success of Genasense Figure 7: Key factors in the relative success of PEG-Intron




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/6538

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 29/11/2009 18:08:06
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use
Web Address:
http://www.researchandmarkets.com/reports/6538
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €1,048.00 + EUR€ 50.00 Shipping/Handling *
Electronic €1,276.00
* Shipping/Handling is only charged once per order.


Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 29/11/2009 18:08:06

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)